Inhibitor Therapeutics, Inc.
INTI
$0.0514
-$0.0086-14.33%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.42% | 5.79% | 37.87% | 116.42% | 210.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.41% | 34.87% | 81.84% | 197.30% | 417.56% |
| Operating Income | -7.41% | -34.87% | -81.84% | -197.30% | -417.56% |
| Income Before Tax | -10.34% | -129.22% | -127.09% | -127.06% | -124.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.34% | -129.37% | -127.22% | -127.19% | -125.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.34% | -129.37% | -127.22% | -127.19% | -125.00% |
| EBIT | -7.41% | -34.87% | -81.84% | -197.30% | -417.56% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -10.23% | -168.58% | -159.26% | -155.72% | -149.03% |
| Normalized Basic EPS | -10.91% | -47.37% | -105.66% | -283.33% | -816.67% |
| EPS Diluted | -10.23% | -176.82% | -165.43% | -160.86% | -153.17% |
| Normalized Diluted EPS | -10.91% | -47.37% | -105.66% | -283.33% | -816.67% |
| Average Basic Shares Outstanding | 0.18% | -18.96% | -34.73% | -45.38% | -53.04% |
| Average Diluted Shares Outstanding | 0.18% | -18.96% | -34.73% | -45.38% | -53.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
